ADAMTS13

Chr 9AR

ADAM metallopeptidase with thrombospondin type 1 motif 13

Also known as: ADAM-TS13, ADAMTS-13, C9orf8, VWFCP, vWF-CP

This metalloprotease cleaves von Willebrand factor multimers in plasma to regulate platelet thrombus formation and prevent excessive clotting. Biallelic mutations cause hereditary thrombotic thrombocytopenic purpura with autosomal recessive inheritance. The gene shows very low constraint against loss-of-function variants (pLI near zero), consistent with the recessive inheritance pattern where heterozygous carriers are typically unaffected.

OMIMResearchSummary from RefSeq, OMIM, UniProt
MultiplemechanismARLOEUF 0.681 OMIM phenotype
Clinical SummaryADAMTS13
🧬
Gene-Disease Validity (ClinGen)
congenital thrombotic thrombocytopenic purpura · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.68LOEUF
pLI 0.000
Z-score 3.70
OE 0.52 (0.390.68)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
1.56Z-score
OE missense 0.85 (0.800.90)
734 obs / 863.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.52 (0.390.68)
00.351.4
Missense OE0.85 (0.800.90)
00.61.4
Synonymous OE0.94
01.21.6
LoF obs/exp: 35 / 67.9Missense obs/exp: 734 / 863.1Syn Z: 0.86
DN
0.6744th %ile
GOF
0.7126th %ile
LOF
0.2678th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

ADAMTS13 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Aortic Valve Stenosis

Platelet Adhesion in the Pathobiology of Aortic Stenosis

ACTIVE NOT RECRUITING
NCT05550896University of VirginiaStarted 2023-01-03
Echocardiogaphy
Venous Thromboembolism

Variations in the Hemostatic System Induced by a Standardized Walking Test

RECRUITING
NCT06418633Phase NACentre Hospitalier Universitaire de NīmesStarted 2025-02-11
60-minute walking testStatic blood testPost-effort blood test
Venous Thromboembolism (VTE)NSCLC (Advanced Non-small Cell Lung Cancer)

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer

RECRUITING
NCT07288632University Of PerugiaStarted 2024-02-09
Acute Ischemic Stroke

A Study of TAK-755 in Adults With Acute Ischemic Stroke

RECRUITING
NCT07392450Phase PHASE2TakedaStarted 2026-04-07
TAK-755Placebo
Acute Respiratory Distress Syndrome

Association Between the Level of EV-TF and the Occurence of Pulmonary Embolism in Patients With ARDS

RECRUITING
NCT05855317Assistance Publique Hopitaux De MarseilleStarted 2023-10-31
Blood sample
Thrombotic Thrombocytopenic Purpura (TTP)

A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma

NOT YET RECRUITING
NCT07353099TakedaStarted 2026-04-30
No Intervention
Thrombotic Thrombocytopenic Purpura

Aspirin for Prophylaxis of TTP

NOT YET RECRUITING
NCT05568147Phase PHASE2, PHASE3The First Affiliated Hospital of Soochow UniversityStarted 2022-10-01
Aspirin tabletPlacebo
Septic Shock

Therapeutic Plasma Exchange in Septic Shock: A Pilot Study

RECRUITING
NCT05093075Phase PHASE2University of ManitobaStarted 2023-06-01
Therapeutic Plasma Exchange
Thrombotic Thrombocytopenic Purpura (TTP)

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

RECRUITING
NCT06441578TakedaStarted 2024-05-30
Recombinant ADAMTS13
Thrombotic Microangiopathies

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

RECRUITING
NCT06291025Phase NAUniversity Hospital, RouenStarted 2024-04-10
PEX-FREE
Thrombotic Thrombocytopenic PurpuraCongenital Thrombotic Thrombocytopenic PurpuraFamilial Thrombotic Thrombocytopenic Purpura

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

RECRUITING
NCT01257269Insel Gruppe AG, University Hospital BernStarted 2006-10
Observation
TTP - Thrombotic Thrombocytopenic Purpura

Italian iTTP Registry

RECRUITING
NCT06376786Fondazione Luigi VillaStarted 2024-06-20
Clinical Literature
Open Research Assistant →